Enamine Ltd.

The abstract submission deadline for the Enamine Drug Discovery Conference has been extended to August 17, 2026! If you are interested in presenting your work at the conference, please refer to the abstract submission guidelines and submit your abstract via the submission form available here: https://lnkd.in/diY43xdV The Enamine Drug Discovery Conference will take place on September 20–23, 2026, in Riga, Latvia. The event will bring together experts in Organic, Medicinal, and Computational Chemistry, as well as Biology, to discuss current directions and challenges in Drug Discovery. Register here: https://lnkd.in/dGtXY8Ex

Molecule of the week EN300-26866135 More details: https://lnkd.in/dKu5vv-S Discover all the molecules of the week here: https://lnkd.in/d9vmpXGR #Enamine #molecule #chemistry #science #drugdiscovery

If you work with C–S bond formation, you know the struggle with unstable, harsh-smelling thiols and catalyst poisoning. Our new building block, 4-((tert-Butylthio)methyl) morpholine, offers a much cleaner workaround. It belongs to the dialkylaminomethyl sulfide class and works similarly to its methyl analog (https://lnkd.in/dSvJWner) from the previously published post. ❔ How it works at the bench: ✅ Controlled release: The reagent stays in equilibrium with an iminium/thiolate pair. By releasing the tert-butylthiolate at a low steady-state concentration, it keeps your catalyst safe from poisoning during metal-catalyzed couplings. ✅ No harsh odors: It is bench-stable and significantly reduces the smell typical for this type of chemistry. ✅ Scope: Works reliably with various aryl electrophiles (chlorides, bromides, triflates) and tolerates sensitive functional groups like esters, ketones, aldehydes, and heterocycles. ✅ Note on sterics: Because of the bulky t-Bu group, sterically hindered substrates will just need a bit more time to react. 🛒 You can buy this exact building block right now on https://lnkd.in/diUHV7MR. 🔬 To explore more details and discover related reagents for your synthesis, check out our Reagents for Synthesis https://lnkd.in/dtxGWfQw. 📖 For further insights into the reaction mechanism, check the full paper hereм https://lnkd.in/dsWTdmmM #OrganicSynthesis #MedicinalChemistry #Enamine #BuildingBlocks

Check out the recent paper: “Design of Potent and Selective BCL6 Transcriptional Chemical Inducers of Proximity through Linker Optimization”, co-authored by Fang-Chi (Cheryl) Chang, Veronika Shoba, Oleh Shyshlyk, Andriy Frolov, Daniil Skrypnik, Halyna Bubela, Yuliia Holota 🇺🇦, Corentine Laurin, Rodrigo Rodriguez, Avery Sader, Timur Savchenko, Petro Borysko, Armand Cognetta, and Oleksandr Grygorenko. This study describes the medicinal chemistry optimization of BCL6 TCIPs through systematic linker engineering. A focused library of 66 heterobifunctional analogues derived from JQ1 and BI-3812 was evaluated for ternary complex formation, cellular potency, and selectivity. Linker rigidification and incorporation of cyclic elements significantly improved cellular selectivity, enhanced solubility, and increased the plasma exposure in mice. Together, these findings establish the linker architecture as a critical determinant of TCIP performance. Read more: https://lnkd.in/dg7AvUFw

Spirocyclic compounds are transforming medicinal chemistry by introducing novel, selective, and highly efficient molecular architectures into clinical practice. Recent FDA approvals, such as revumenib for leukemia (2024) and delgocitinib for eczema (2025), highlight their potential. Spirocyclic linkers, as compact molecular fragments, enhance the three-dimensionality of molecules, improving solubility and reducing metabolic susceptibility. The next frontier, trispirocyclic compounds, has only recently emerged, appearing in several patents. Seize the opportunity to explore this uncharted chemical space with a library of over 100 bifunctional trispirocyclic compounds from Enamine’s latest collection: https://lnkd.in/dfjzCmsM Try our spirocycles in your research!

Join us at these upcoming conferences: - 10th EuChemS Chemistry Congress, July 12-16, Antwerp, Belgium - CHIRALITY 2026, July 14-17, Santiago de Compostela, Spain - Computational Chemistry GRC, July 19 - 24, Barcelona, Spain We will be happy to meet you, discuss the latest developments in Drug Discovery, and explore new opportunities for collaboration. Dmytro Volochnyuk, Serhiy Ryabukhin, Oleksandr Grygorenko, Oleksandr Liashuk, Dmytro Leha, Olexandr Pashenko, Olesia Volovenko, Iryna Kravets, Dmytro Dudenko #ECC10 #CHIRALITY2026

Molecule of the week EN300-46883942 More details: https://bit.ly/4xXSwSx Discover all the molecules of the week here: https://lnkd.in/d9vmpXGR #Enamine #molecule #chemistry #science #drugdiscovery

Only 80 days remain until the Enamine Drug Discovery Conference!   Taking place on September 20–23, 2026, in Riga, Latvia, the conference will bring together experts in Organic, Medicinal, and Computational Chemistry, as well as Biology, to discuss current directions and challenges in Drug Discovery.   Registration is open: https://lnkd.in/dGtXY8Ex The list of confirmed speakers continues to grow: https://lnkd.in/erthgf_Q More information: https://lnkd.in/dr2Z8y4g

Enamine Ltd. has always been a research-driven company, and in recent years, its scientific activities have expanded significantly. The number of publications affiliated with Enamine Ltd. increased from about 30 per year just a decade ago to over 120 in 2025. Given this remarkable growth, the company is strengthening its research leadership by introducing an independent role of Chief Science and Innovation Officer – a peer to the Chief Scientific Officer – and appointing Prof. Dr. Oleksandr Grygorenko to this position. Oleksandr Grygorenko currently serves as Head of the Department of Organic Chemistry at Taras Shevchenko National University of Kyiv and Vice Director for Scientific Research at Enamine Scientific Research Institute. He has also been working at Enamine Ltd. as a consulting scientist for many years. With an outstanding publication record approaching 300 scientific articles, as well as extensive experience in scientific leadership and supervision, Prof. Grygorenko will further strengthen Enamine's leading position in chemical research and innovation.

💡 Rethinking carbonyl replacement in medicinal chemistry! Among the many bioisosteric strategies, gem-difluorinated motifs have emerged as particularly attractive alternatives to carbonyl groups. CF₂-containing units and difluoromethylene motifs can reproduce key steric and electronic features of carbonyl functionalities while introducing properties highly desirable in lead optimization. Why are medicinal chemists increasingly interested in these motifs? 🔹 Enhanced metabolic stability by avoiding carbonyl-specific biotransformations 🔹 Improved resistance to reduction and hydrolysis 🔹 Fine-tuning of lipophilicity and molecular recognition 🔹 Opportunities to improve potency and ADME profiles Several examples already show that replacing a carbonyl group with a gem-difluorinated motif can significantly improve biological activity, from more potent enzyme inhibitors to antimalarial analogues with enhanced efficacy (https://lnkd.in/dHHgvhYV). At Enamine, we continuously design, synthesize, and expand our portfolio of gem-difluorinated building blocks and screening compounds, focusing on motifs relevant for carbonyl bioisosteric replacement. Our collection is regularly updated based on emerging medicinal chemistry trends and customer needs. Looking for a specific Ar–CF₂–R scaffold, a novel fluorinated building block, or a custom-designed bioisostere? Chances are we’re already working on it—or can make it happen via our EnamineStore 👉 https://enaminestore.com #MedicinalChemistry #DrugDiscovery #Bioisosteres #FluorineChemistry #CarbonylBioisosteres #LeadOptimization #BuildingBlocks #FluorinatedCompounds #Enamine #EnamineStore